Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A McDowell

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Antimicrobial Agents and Chemotherapy|May 19, 2000
Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adultsJ A McDowell, G E Chittick, C P Stevens, et al.
Antimicrobial Agents and Chemotherapy|February 27, 1999
Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adultsP N Kumar, D E Sweet, J A McDowell, et al.
Indian Journal of Cancer|March 7, 2008
Validation of the University of Washington quality of life questionnaires for head and neck cancer patients in IndiaA K D'cruz, B Yueh, A K Das, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1999
Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance studyJ A McDowell, G E Chittick, J R Ravitch, et al.
Pharmacotherapy|August 24, 1999
Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of foodG E Chittick, C Gillotin, J A McDowell, et al.
Antimicrobial Agents and Chemotherapy|February 27, 1999
Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected childrenW Hughes, J A McDowell, J Shenep, et al.
Archives of Otolaryngology--Head & Neck Surgery|November 1, 2001
Randomized trial of amplification strategiesB Yueh, P E Souza, J A McDowell, et al.
Pediatrics|April 2, 1999
A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 TeamM W Kline, S Blanchard, C V Fletcher, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Antimicrobial Agents and Chemotherapy|May 19, 2000
Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adultsJ A McDowell, G E Chittick, C P Stevens, et al.
Antimicrobial Agents and Chemotherapy|February 27, 1999
Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adultsP N Kumar, D E Sweet, J A McDowell, et al.
Indian Journal of Cancer|March 7, 2008
Validation of the University of Washington quality of life questionnaires for head and neck cancer patients in IndiaA K D'cruz, B Yueh, A K Das, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1999
Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance studyJ A McDowell, G E Chittick, J R Ravitch, et al.
Pharmacotherapy|August 24, 1999
Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of foodG E Chittick, C Gillotin, J A McDowell, et al.
Antimicrobial Agents and Chemotherapy|February 27, 1999
Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected childrenW Hughes, J A McDowell, J Shenep, et al.
Archives of Otolaryngology--Head & Neck Surgery|November 1, 2001
Randomized trial of amplification strategiesB Yueh, P E Souza, J A McDowell, et al.
Pediatrics|April 2, 1999
A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 TeamM W Kline, S Blanchard, C V Fletcher, et al.
Pageof 2